Exelixis, Inc. (EXEL) Stock Analysis
Breakout setup
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $48.16, but acceptable to hold if already in. Reasons: Concentration risk — Product: CABOMETYX; Analyst target reached - limited upside remaining.
Exelixis is an oncology company with two marketed cabozantinib products -- CABOMETYX (RCC, HCC, DTC, pNET/epNET) and COMETRIQ (MTC) -- generating $2.12 billion in net product revenue in 2025. Ex-U.S. commercialization is handled by Ipsen (all markets except Japan) and Takeda... Read more
Hold if already holding. Not a fresh buy at $48.16, but acceptable to hold if already in. Reasons: Concentration risk — Product: CABOMETYX; Analyst target reached - limited upside remaining. Chart setup: Golden cross, above all MAs, RSI 64, MACD bullish. Downgraded from BUY WAIT — price $48.16 has reached target $47.94. No upside to wait for. Score 6.5/10, moderate confidence.
Passes 6/7 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 85d clear, semi cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductCABOMETYX10-K Item 1A: 'Our ability to grow our company is dependent upon the commercial success of CABOMETYX in its approved indications'
- MEDIUMcounterpartyIpsen10-K Item 1: 'Outside the U.S., we rely on collaboration partners for the commercialization of our cabozantinib products; Ipsen is responsible for all territories outside of the U.S. and Japan'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker·1 ceiling hit
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $48.16, but acceptable to hold if already in. Reasons: Concentration risk — Product: CABOMETYX; Analyst target reached - limited upside remaining. Chart setup: Golden cross, above all MAs, RSI 64, MACD bullish. Downgraded from BUY WAIT — price $48.16 has reached target $47.94. No upside to wait for. Target $47.94 (-0.5%), stop $42.20 (−14.1%), A.R:R -0.9:1. Score 6.5/10, moderate confidence.
Take-profit target: $47.94 (+8.0% upside). Target $47.94 (-0.5%), stop $42.20 (−14.1%), A.R:R -0.9:1. Stop-loss: $42.20.
Concentration risk — Product: CABOMETYX; Analyst target reached - limited upside remaining; Near 52-week high (2.9% away).
Exelixis, Inc. trades at a P/E of 15.9 (forward 11.9). TrendMatrix value score: 7.2/10. Verdict: Hold.
26 analysts cover EXEL with a consensus score of 3.8/5. Average price target: $49.
What does Exelixis, Inc. do?Exelixis is an oncology company with two marketed cabozantinib products -- CABOMETYX (RCC, HCC, DTC, pNET/epNET) and...
Exelixis is an oncology company with two marketed cabozantinib products -- CABOMETYX (RCC, HCC, DTC, pNET/epNET) and COMETRIQ (MTC) -- generating $2.12 billion in net product revenue in 2025. Ex-U.S. commercialization is handled by Ipsen (all markets except Japan) and Takeda (Japan); zanzalintinib is in multiple late-stage trials.